- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Full Field Digital Mammography May Miss Interval Breast Cancers
Full field digital mammography, performed instead of screen film mammography, finds fewer interval breast cancers.
The switch to full field digital mammography (FFDM) has changed the mammographic presentation of interval breast cancer, with fewer interval cancers presenting in association with microcalcifications, according to a study published in the European Journal of Radiology.
Researchers from Ireland sought to assess the impact of FFDM on the classification of interval breast cancers and to compare the mammographic features of interval cancers at FFDM and screen film mammography (SFM).
The researchers looked at 76 cases of interval breast cancer following FFDM screening and 62 following SFM screening. Five consultant breast radiologists assessed prior screening mammograms. The review classified cases as missed, minimal signs, occult, or true interval breast cancer. Mammographic features of the interval cancer at diagnosis and any abnormality identified on the prior screening mammogram were recorded.
The results showed that there was not much difference between FFDM and SFM for missed cancers, but there were significantly fewer interval cancers presenting as microcalcifications following SFM.
The interval breast cancers did not show up as frequently with FFDM, so this can be problematic, concluded the researchers.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.
